Polycystic ovary syndrome

Ricardo Azziz*, Enrico Carmina, Zijiang Chen, Andrea Dunaif, Joop S.E. Laven, Richard S. Legro, Daria Lizneva, Barbara Natterson-Horowtiz, Helena J. Teede, Bulent O. Yildiz

*Corresponding author for this work

Research output: Contribution to journalReview article

175 Citations (Scopus)

Abstract

Polycystic ovary syndrome (PCOS) affects 5-20% of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM)-with excessive androgen production by the ovaries being a key feature of PCOS. Metabolic dysfunction characterized by insulin resistance and compensatory hyperinsulinaemia is evident in the vast majority of affected individuals. PCOS increases the risk for type 2 diabetes mellitus, gestational diabetes and other pregnancy-related complications, venous thromboembolism, cerebrovascular and cardiovascular events and endometrial cancer. PCOS is a diagnosis of exclusion, based primarily on the presence of hyperandrogenism, ovulatory dysfunction and PCOM. Treatment should be tailored to the complaints and needs of the patient and involves targeting metabolic abnormalities through lifestyle changes, medication and potentially surgery for the prevention and management of excess weight, androgen suppression and/or blockade, endometrial protection, reproductive therapy and the detection and treatment of psychological features. This Primer summarizes the current state of knowledge regarding the epidemiology, mechanisms and pathophysiology, diagnosis, screening and prevention, management and future investigational directions of the disorder.

Original languageEnglish (US)
Article number16057
JournalNature Reviews Disease Primers
Volume2
DOIs
StatePublished - Aug 11 2016

Fingerprint

Polycystic Ovary Syndrome
Hyperandrogenism
Androgens
Gestational Diabetes
Pregnancy Complications
Venous Thromboembolism
Hyperinsulinism
Endometrial Neoplasms
Type 2 Diabetes Mellitus
Insulin Resistance
Life Style
Ovary
Epidemiology
Therapeutics
Psychology
Weights and Measures

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., ... Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2, [16057]. https://doi.org/10.1038/nrdp.2016.57
Azziz, Ricardo ; Carmina, Enrico ; Chen, Zijiang ; Dunaif, Andrea ; Laven, Joop S.E. ; Legro, Richard S. ; Lizneva, Daria ; Natterson-Horowtiz, Barbara ; Teede, Helena J. ; Yildiz, Bulent O. / Polycystic ovary syndrome. In: Nature Reviews Disease Primers. 2016 ; Vol. 2.
@article{84d0d70fba744b10920c9323f0e6c972,
title = "Polycystic ovary syndrome",
abstract = "Polycystic ovary syndrome (PCOS) affects 5-20{\%} of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM)-with excessive androgen production by the ovaries being a key feature of PCOS. Metabolic dysfunction characterized by insulin resistance and compensatory hyperinsulinaemia is evident in the vast majority of affected individuals. PCOS increases the risk for type 2 diabetes mellitus, gestational diabetes and other pregnancy-related complications, venous thromboembolism, cerebrovascular and cardiovascular events and endometrial cancer. PCOS is a diagnosis of exclusion, based primarily on the presence of hyperandrogenism, ovulatory dysfunction and PCOM. Treatment should be tailored to the complaints and needs of the patient and involves targeting metabolic abnormalities through lifestyle changes, medication and potentially surgery for the prevention and management of excess weight, androgen suppression and/or blockade, endometrial protection, reproductive therapy and the detection and treatment of psychological features. This Primer summarizes the current state of knowledge regarding the epidemiology, mechanisms and pathophysiology, diagnosis, screening and prevention, management and future investigational directions of the disorder.",
author = "Ricardo Azziz and Enrico Carmina and Zijiang Chen and Andrea Dunaif and Laven, {Joop S.E.} and Legro, {Richard S.} and Daria Lizneva and Barbara Natterson-Horowtiz and Teede, {Helena J.} and Yildiz, {Bulent O.}",
year = "2016",
month = "8",
day = "11",
doi = "10.1038/nrdp.2016.57",
language = "English (US)",
volume = "2",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

Azziz, R, Carmina, E, Chen, Z, Dunaif, A, Laven, JSE, Legro, RS, Lizneva, D, Natterson-Horowtiz, B, Teede, HJ & Yildiz, BO 2016, 'Polycystic ovary syndrome', Nature Reviews Disease Primers, vol. 2, 16057. https://doi.org/10.1038/nrdp.2016.57

Polycystic ovary syndrome. / Azziz, Ricardo; Carmina, Enrico; Chen, Zijiang; Dunaif, Andrea; Laven, Joop S.E.; Legro, Richard S.; Lizneva, Daria; Natterson-Horowtiz, Barbara; Teede, Helena J.; Yildiz, Bulent O.

In: Nature Reviews Disease Primers, Vol. 2, 16057, 11.08.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Polycystic ovary syndrome

AU - Azziz, Ricardo

AU - Carmina, Enrico

AU - Chen, Zijiang

AU - Dunaif, Andrea

AU - Laven, Joop S.E.

AU - Legro, Richard S.

AU - Lizneva, Daria

AU - Natterson-Horowtiz, Barbara

AU - Teede, Helena J.

AU - Yildiz, Bulent O.

PY - 2016/8/11

Y1 - 2016/8/11

N2 - Polycystic ovary syndrome (PCOS) affects 5-20% of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM)-with excessive androgen production by the ovaries being a key feature of PCOS. Metabolic dysfunction characterized by insulin resistance and compensatory hyperinsulinaemia is evident in the vast majority of affected individuals. PCOS increases the risk for type 2 diabetes mellitus, gestational diabetes and other pregnancy-related complications, venous thromboembolism, cerebrovascular and cardiovascular events and endometrial cancer. PCOS is a diagnosis of exclusion, based primarily on the presence of hyperandrogenism, ovulatory dysfunction and PCOM. Treatment should be tailored to the complaints and needs of the patient and involves targeting metabolic abnormalities through lifestyle changes, medication and potentially surgery for the prevention and management of excess weight, androgen suppression and/or blockade, endometrial protection, reproductive therapy and the detection and treatment of psychological features. This Primer summarizes the current state of knowledge regarding the epidemiology, mechanisms and pathophysiology, diagnosis, screening and prevention, management and future investigational directions of the disorder.

AB - Polycystic ovary syndrome (PCOS) affects 5-20% of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM)-with excessive androgen production by the ovaries being a key feature of PCOS. Metabolic dysfunction characterized by insulin resistance and compensatory hyperinsulinaemia is evident in the vast majority of affected individuals. PCOS increases the risk for type 2 diabetes mellitus, gestational diabetes and other pregnancy-related complications, venous thromboembolism, cerebrovascular and cardiovascular events and endometrial cancer. PCOS is a diagnosis of exclusion, based primarily on the presence of hyperandrogenism, ovulatory dysfunction and PCOM. Treatment should be tailored to the complaints and needs of the patient and involves targeting metabolic abnormalities through lifestyle changes, medication and potentially surgery for the prevention and management of excess weight, androgen suppression and/or blockade, endometrial protection, reproductive therapy and the detection and treatment of psychological features. This Primer summarizes the current state of knowledge regarding the epidemiology, mechanisms and pathophysiology, diagnosis, screening and prevention, management and future investigational directions of the disorder.

UR - http://www.scopus.com/inward/record.url?scp=85006186623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006186623&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2016.57

DO - 10.1038/nrdp.2016.57

M3 - Review article

C2 - 27510637

AN - SCOPUS:85006186623

VL - 2

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 16057

ER -

Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016 Aug 11;2. 16057. https://doi.org/10.1038/nrdp.2016.57